Apex Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Apex Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$3.08M	Sell	48,143 -5,108	-10%	-$322K	0.07%	178
2015 Q4	$3.66M	Buy	53,251 +46,718	+715%	+$3.09M	0.08%	164
2015 Q3	$387K	Hold	6,533	–	–	0.01%	232
2015 Q2	$435K	Sell	6,533 -33	-0.5%	-$2.17K	0.01%	231
2015 Q1	$424K	Buy	6,566 +33	+0.5%	+$2.07K	0.01%	230
2014 Q4	$386K	Buy	6,533 +133	+2%	+$7.5K	0.01%	234
2014 Q3	$328K	Sell	6,400 -1,000	-14%	-$50K	0.01%	229
2014 Q2	$359K	Hold	7,400	–	–	0.01%	249
2014 Q1	$384K	Buy	+7,400	New	+$394K	0.01%	236

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apex Capital Management's BMY Position: Q1 2016 in Review

Apex Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 9.6% in Q1 2016, selling an estimated $322K and leaving 48,143 shares worth $3.08M. The position accounts for 0.07% of the portfolio, ranked #178.

Apex Capital Management first reported a position in BMY in Q1 2014 and has held it in 9 quarters since. The position peaked at $3.66M in Q4 2015. 1,523 funds tracked by Wall St. Rank hold BMY as of Q1 2016.

Apex Capital Management held 48,143 shares of Bristol-Myers Squibb worth $3.08M as of Q1 2016.
Apex Capital Management sold 5,108 Bristol-Myers Squibb shares in Q1 2016, an estimated $322K.
Bristol-Myers Squibb made up 0.07% of Apex Capital Management's portfolio in Q1 2016, its #178 holding.
Apex Capital Management first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 9 quarters since.
Apex Capital Management's Bristol-Myers Squibb position peaked at $3.66M in Q4 2015.
1,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.